Last reviewed · How we verify

Nirogacestat and Famotidine

SpringWorks Therapeutics, Inc. · Phase 1 active Small molecule

Nirogacestat and Famotidine is a Small molecule drug developed by SpringWorks Therapeutics, Inc.. It is currently in Phase 1 development. Also known as: Histamine H2-Receptor Antagonist (H2 Blocker).

At a glance

Generic nameNirogacestat and Famotidine
Also known asHistamine H2-Receptor Antagonist (H2 Blocker)
SponsorSpringWorks Therapeutics, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Nirogacestat and Famotidine

What is Nirogacestat and Famotidine?

Nirogacestat and Famotidine is a Small molecule drug developed by SpringWorks Therapeutics, Inc..

Who makes Nirogacestat and Famotidine?

Nirogacestat and Famotidine is developed by SpringWorks Therapeutics, Inc. (see full SpringWorks Therapeutics, Inc. pipeline at /company/springworks-therapeutics-inc).

Is Nirogacestat and Famotidine also known as anything else?

Nirogacestat and Famotidine is also known as Histamine H2-Receptor Antagonist (H2 Blocker).

What development phase is Nirogacestat and Famotidine in?

Nirogacestat and Famotidine is in Phase 1.

Related